2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Serologic Tests, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Non-Hodgkin Lymphoma, Research, Translational Research, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3951 Clonal hematopoiesis and monoclonal gammopathy of undetermined significance: Two precursors and their effect on survival

Nicholas J Boddicker, PhD, Angelica Macauda, PhD2, Cristine Allmer, BS3, Danelle Moonen4, Aaron Norman5, Alyssa Ione Clay-Gilmour, PhD6, Janet E. Olson, PhD7, Mrinal M. Patnaik, MD, MBBS8, Esteban Braggio, PhD9, David L Murray, MD, PhD10, Shaji Kumar, MD11, Susan L. Slager, PhD12, Celine Vachon, PhD13
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 University of South Carolina, Columbia, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Phoenix, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States

Introduction: Monoclonal gammopathy of undetermined significance (MGUS) is a precursor to multiple myeloma, and clonal hematopoiesis (CH) is a precursor to both myeloid and lymphoid malignancies. Both precursors are common in the general population, with prevalences between 5-10% and increase with age. Individuals with these precursors are at increased risk of hematologic malignancies as well as death. Here, we investigate the association of MGUS, CH, and their combination with all-cause mortality in a large screening cohort. 

Methods: Study participants were sampled from the two sources: the Mayo Clinic Biobank, a large-scale biorepository of individuals recruited from primary care clinics between 2009 and 2016, and individuals diagnosed with MGUS in a clinical dysproteinemia registry over a similar time period. Individuals were included if they had no prior history of lymphoid malignancy, were older than 50 years, and resided in the 27 counties surrounding Mayo Clinic (Rochester, Minnesota) at the time of consent. Individuals were tested for MGUS using either serum electrophoresis followed by immunofixation or by the sensitive MALDI-TOF mass spectrometry or MASS FIX. CH was detected using whole-exome sequencing (~48X coverage) of whole-blood DNA in 291 genes related to hematologic malignancies (minimum variant allele fraction of 2%). Deaths were identified using the electronic health records and the Minnesota death registry. Survival probabilities were estimated using the Kaplan-Meier method, with follow-up time defined from date of blood sample collection to earliest date of death, withdrawal, or last follow up (12/31/2024). Cox proportional hazards regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CI). MGUS was analyzed as any detectable M-protein as well as limited to M-protein>0.1 g/dL. All models were adjusted for age and sex.

Results: A total of 16,873 individuals were screened for MGUS and CH; 2388 (14.2%) individuals were positive for MGUS (2059 from Biobank and 329 from the clinical registry), and 1883 (11.2%) were positive for CH with genes DNMT3A, TET2, and ASXL1 harboring 61% of all mutations identified. 345 (2.0%) individuals had both MGUS and CH. Median follow-up time was 12.2 years with a total of 3920 deaths. Individuals with MGUS had a 10-year survival probability of 73.3% vs 86.1% in individuals without MGUS. After adjusting for age and sex, individuals with MGUS had significantly increased risk of death compared to individuals without MGUS (HR=1.23, 95%CI:1.14-1.34, P<0.01). The magnitude of association increased when restricting to individuals with an M-protein>0.1 g/dL (HR=1.39, 95%CI:1.21-1.59, P<0.01). The 10-year survival probability was 70.9% for individuals with CH compared to 86.0% for those without CH. After adjusting for age and sex, individuals with CH had significantly increased risk of death compared to individuals without CH (HR=1.25, 95%CI:1.16-1.36, P<0.01). In a multivariate model that included MGUS, CH and their interaction term, along with age and sex, there was no evidence of a statistically significant interaction on risk of death (P=0.21). The 10-year survival probability was 87.5% for no precursor conditions, 76.2% for MGUS only, 74.0% for CH-only, and 55.9% for individuals with CH and MGUS. Using Cox proportional hazards, adjusting for age and sex, individuals with both MGUS and CH had the highest risk of death (HR=1.68, 95%CI:1.44-1.96, P<0.01), with similar risks for individuals with CH (HR=1.22, 95%CI:1.11-1.34, P<0. 01) or MGUS alone (HR=1.20, 95%CI:1.10-1.31, P<0.01). When restricting analyses to M-protein >0.1 g/dL, the HR for those with both conditions increased (HR=1.82, 95%CI:1.39-2.38, P<0.01).

Conclusions: In this large screening study of two hematological precursor conditions, we confirmed that both precursors are independently associated with increased all-cause mortality. Individuals with both precursor conditions had the highest risk of death. Notably, individuals with both had significantly higher risk than either precursor alone. Further work is needed to understand the associations of these precursors with cause-specific death.

Nicholas J Boddicker, PhD: No relevant conflicts of interest to declare.